Profile Image

Elaine Peskind, MD

Personal Statement

I am Co-Director of the VA VISN 20 (Northwest Network) Mental Illness Research, Education, and Clinical Center (MIRECC). I am also the Friends of Alzheimer’s Research Professor of Psychiatry and Behavioral Sciences at the University of Washington (UW) School of Medicine and am Associate Director of the UW Alzheimer’s Disease Research Center. My research over the past 30 years has addressed cognitive and behavioral problems and cerebrospinal fluid (CSF) biomarkers in neurodegenerative dementing disorders such as Alzheimer’s disease. More recently, my research has focused on combat trauma posttraumatic stress disorder and the clinical phenomenology as well as neuroimaging and CSF biomarkers of neurodegeneration in combat blast concussion mild traumatic brain injury and in Gulf War Veterans Illness. I continue to conduct single site as well as multi-site large scale studies of CSF biomarkers and pharmacological treatment trials for behavioral disorders and traumatic brain injury.

Summary of my research program:

Blast Concussion Mild Traumatic Brain Injury (mTBI)
Strategies: multimodal neuroimaging: structural and functional magnetic resonance imaging (diffusion tensor imaging [DTI], DTI tractography, macromolecular proton fraction mapping, resting state and task-based functional MRI; susceptibility-weighted imaging, FDG-positron emission tomography [PET]; cerebrospinal fluid and plasma biomarkers; genetic risk factors; clinical, neurocognitive and behavioral assessments,

Gulf War Veterans Illness (GWVI)
Strategies: multimodal neuroimaging and CSF and plasma biomarkers as described above, epigenetics, pain sensitivity testing and ability to activate endogenous opioid systems, and functional activity of paraoxonase I, the enzyme that metabolizes organophosphate insecticides.

Cerebrospinal Fluid and Plasma Biomarkers of Neurodegeneration Strategies: Bead-based multiplex assays using Luminex and Meso-Scale platforms, Quanterix ultra-sensitive platform, and broad-scale mass spectrometry for measurement of proteins, circulating RNAs, microRNAs in collaboration with VA/UW and Institute for Systems Biology investigators.

Pharmacologic Treatment of Disruptive Agitation in Alzheimer’s Disease (AD)
Strategies: Alzheimer’s Disease Cooperative Study multi-center randomized placebo-controlled trial of the alpha-1 adrenoreceptor antagonist, prazosin, for treatment of disruptive agitation in AD.

Department Affiliations

Recent Publications

Cerebrospinal fluid soluble insulin receptor levels in Alzheimer's disease.
(2024 Apr-Jun)
Alzheimers Dement (Amst) 16(2): e12603
Thomas P, Leclerc M, Evitts K, Brown C, Miller W, Hanson AJ, Banks WA, Gibbons L, Domoto-Reilly K, Jayadev S, Li G, Peskind E, Young JE, Consortium for the early identification of Alzheimer's disease‐Quebec (CIMA‐Q), Calon F, Rhea EM

Increased [(18)F]Fluorodeoxyglucose Uptake in the Left Pallidum in Military Veterans with Blast-Related Mild Traumatic Brain Injury: Potential as an Imaging Biomarker and Mediation with Executive Dysfunction and Cognitive Impairment.
(2024 May 8)
J Neurotrauma
Terry G, Pagulayan KF, Muzi M, Mayer C, Murray DR, Schindler AG, Richards TL, McEvoy C, Crabtree A, McNamara C, Means G, Muench P, Powell JR, Mihalik JP, Thomas RG, Raskind MA, Peskind ER, Meabon JS

CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury.
(2024 Apr 9)
Neurology 102(7): e209197
Li G, Iliff J, Shofer J, Mayer CL, Meabon J, Cook D, Pagulayan KF, Raskind MA, Zetterberg H, Blennow K, Peskind ER

Inflammatory biomarkers for neurobehavioral dysregulation in former American football players: findings from the DIAGNOSE CTE Research Project.
(2024 Feb 9)
J Neuroinflammation 21(1): 46
van Amerongen S, Pulukuri SV, Tuz-Zahra F, Tripodis Y, Cherry JD, Bernick C, Geda YE, Wethe JV, Katz DI, Alosco ML, Adler CH, Balcer LJ, Ashton NJ, Blennow K, Zetterberg H, Daneshvar DH, Colasurdo EA, Iliff JJ, Li G, Peskind ER, Shenton ME, Reiman EM, Cummings JL, Stern RA, DIAGNOSE CTE Research Project Investigators

APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's disease pathology.
(2024 Apr 3)
Neuron 112(7): 1110-1116.e5
Chemparathy A, Le Guen Y, Chen S, Lee EG, Leong L, Gorzynski JE, Jensen TD, Ferrasse A, Xu G, Xiang H, Belloy ME, Kasireddy N, Peña-Tauber A, Williams K, Stewart I, Talozzi L, Wingo TS, Lah JJ, Jayadev S, Hales CM, Peskind E, Child DD, Roeber S, Keene CD, Cong L, Ashley EA, Yu CE, Greicius MD

Show complete publication list »
Edit Profile